

# Robert Brown

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1418284/robert-brown-publications-by-citations.pdf>  
**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

51 papers	5,021 citations	28 h-index	63 g-index
63 ext. papers	6,028 ext. citations	10.4 avg, IF	5 L-index

#	Paper	IF	Citations
51	Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 5198-208	12.9	1044
50	Whole-genome characterization of chemoresistant ovarian cancer. <i>Nature</i> , <b>2015</b> , 521, 489-94	50.4	890
49	Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. <i>Nature Medicine</i> , <b>2018</b> , 24, 628-637	50.5	410
48	DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. <i>Journal of the National Cancer Institute</i> , <b>2005</b> , 97, 1498-506	9.7	385
47	The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 4420-6	12.9	216
46	CpG island methylation of DNA damage response genes in advanced ovarian cancer. <i>Cancer Research</i> , <b>2005</b> , 65, 8961-7	10.1	213
45	Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 4603-9	2.2	201
44	Poised epigenetic states and acquired drug resistance in cancer. <i>Nature Reviews Cancer</i> , <b>2014</b> , 14, 747-53	11.3	195
43	Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 4528-35	2.2	194
42	Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. <i>Molecular Cancer Therapeutics</i> , <b>2011</b> , 10, 325-35	6.1	168
41	International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis. <i>Gut</i> , <b>2019</b> , 68, 1624-1632	19.2	101
40	Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker. <i>Drug Resistance Updates</i> , <b>2004</b> , 7, 267-78	23.2	98
39	The promises and pitfalls of epigenetic therapies in solid tumours. <i>European Journal of Cancer</i> , <b>2009</b> , 45, 1129-1136	7.5	78
38	Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 4052-62	12.9	75
37	Demethylation of the MCI gene in stage III/IV epithelial ovarian cancer and response to chemotherapy. <i>Gynecologic Oncology</i> , <b>2005</b> , 97, 898-903	4.9	62
36	Epithelial ovarian carcinoma diagnosis by desorption electrospray ionization mass spectrometry imaging. <i>Scientific Reports</i> , <b>2016</b> , 6, 39219	4.9	52
35	Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 2213-2222	12.9	49

34	Temporal stability and determinants of white blood cell DNA methylation in the breakthrough generations study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2015</b> , 24, 221-9	4	43
33	Biomarker Assessment of HR Deficiency, Tumor Mutations, and Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy. <i>Molecular Cancer Research</i> , <b>2018</b> , 16, 1103-1111	6.6	42
32	Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer. <i>Annals of Medicine</i> , <b>2015</b> , 47, 359-69	1.5	41
31	Super-achromatic monolithic microprobe for ultrahigh-resolution endoscopic optical coherence tomography at 800 nm. <i>Nature Communications</i> , <b>2017</b> , 8, 1531	17.4	41
30	Tackling cancer burden in the Middle East: Qatar as an example. <i>Lancet Oncology, The</i> , <b>2012</b> , 13, e501-8	21.7	37
29	HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. <i>Cell Reports</i> , <b>2020</b> , 31, 107625	10.6	34
28	Promoter CpG island methylation of genes in key cancer pathways associates with clinical outcome in high-grade serous ovarian cancer. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 5788-5797	12.9	34
27	Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells. <i>Clinical Epigenetics</i> , <b>2015</b> , 7, 84	7.7	34
26	Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 3097-3104	12.9	32
25	Nrf2, the master redox switch: the Achilles heel of ovarian cancer?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , <b>2014</b> , 1846, 494-509	11.2	28
24	Therapeutic modulation of epigenetic drivers of drug resistance in ovarian cancer. <i>Therapeutic Advances in Medical Oncology</i> , <b>2010</b> , 2, 319-29	5.4	28
23	ABCB1 2677G>T/A genotype and paclitaxel pharmacogenetics in ovarian cancer. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 4127; author reply 4127-9	12.9	24
22	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (ProTYPE). <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 5411-5423	12.9	21
21	Aberrant DNA methylation at genes associated with a stem cell-like phenotype in cholangiocarcinoma tumors. <i>Cancer Prevention Research</i> , <b>2013</b> , 6, 1348-55	3.2	20
20	Genes Predisposed to DNA Hypermethylation during Acquired Resistance to Chemotherapy Are Identified in Ovarian Tumors by Bivalent Chromatin Domains at Initial Diagnosis. <i>Cancer Research</i> , <b>2018</b> , 78, 1383-1391	10.1	19
19	Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer. <i>Modern Pathology</i> , <b>2021</b> , 34, 1185-1193	9.8	15
18	Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study. <i>British Journal of Cancer</i> , <b>2017</b> , 116, 1287-1293	8.7	14
17	Transcriptional implications of intragenic DNA methylation in the oestrogen receptor alpha gene in breast cancer cells and tissues. <i>BMC Cancer</i> , <b>2015</b> , 15, 337	4.8	14

16	DNA methylation profiling to assess pathogenicity of BRCA1 unclassified variants in breast cancer. <i>Epigenetics</i> , <b>2015</b> , 10, 1121-32	5.7	11
15	Variation in NF- $\kappa$ B signaling pathways and survival in invasive epithelial ovarian cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2014</b> , 23, 1421-7	4	11
14	Approaches to target the genome and its epigenome in cancer. <i>Future Medicinal Chemistry</i> , <b>2009</b> , 1, 1481-95	4.95	9
13	Tumor mutational landscape is a record of the pre-malignant state		8
12	Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer. <i>EMBO Molecular Medicine</i> , <b>2021</b> , 13, e13366	12	7
11	Challenges and methodology in the incorporation of biomarkers in cancer clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , <b>2017</b> , 110, 49-61	7	6
10	Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expression <b>2021</b> , 9,		5
9	Is there a Role for Epigenetic Enhancement of Immunomodulatory Approaches to Cancer Treatment?. <i>Current Cancer Drug Targets</i> , <b>2018</b> , 18, 5-15	2.8	3
8	Chromatin accessibility changes at intergenic regions are associated with ovarian cancer drug resistance. <i>Clinical Epigenetics</i> , <b>2021</b> , 13, 122	7.7	3
7	Homologous recombination (HR) deficiency, tumor BRCA1/2 mutations (tmBRCA) and association with response and outcome following platinum monotherapy in high grade serous ovarian cancer (HGSOC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 5576-5576	2.2	2
6	Prospects for epigenetic compounds in the treatment of autoimmune disease. <i>Advances in Experimental Medicine and Biology</i> , <b>2011</b> , 711, 150-61	3.6	2
5	Glycosylated Nanoparticles Derived from RAFT Polymerization for Effective Drug Delivery to Macrophages.. <i>ACS Applied Bio Materials</i> , <b>2020</b> , 3, 5775-5786	4.1	1
4	Epigenetic Therapies in Solid Tumours: From Preclinical Models to Clinical Trial Results <b>2014</b> , 299-317		0
3	Engineering solutions for cancer. <i>Convergent Science Physical Oncology</i> , <b>2017</b> , 3, 010201		
2	Epigenetic biomarkers in ovarian cancer31-40		
1	Epigenetic Therapies <b>2011</b> , 189-202		